Search | IOVS | ARVO Journals

Showing 1 – 20 of 23

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina October 2014

CNGB3 -Achromatopsia Clinical Trial With CNTF: Diminished Rod Pathway Responses With No Evidence of Improvement in Cone Function

PDF

Wadih M. Zein; Brett G. Jeffrey; Henry E. Wiley; Amy E. Turriff; Santa J. Tumminia; Weng Tao; Ronald A. Bush; Dario Marangoni; Rong Wen; Lisa L. Wei; Paul A. Sieving
TAGS: achromatopsia, ciliary neurotrophic factor, retinal cone, rod photoreceptors, implants, eye, electroretinography
Invest. Ophthalmol. Vis. Sci.. 2014; 55(10):6301-6308. https://doi.org/10.1167/iovs.14-14860

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2013

Generation of Combination PDGF / VEGF-antagonist ECT devices

Vincent Ling; Arne Nystuen; Susan Elliott; Lisa Orecchio; Brenda Dean; Konrad Kauper; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3290.

ARVO Annual Meeting Abstract June 2013

Feasibility of Cryopreservation of the Encapsulated Cell Technology Devices

Cahil McGovern; John Duggan; Crystal Cortellessa; Sandy Sherman; Melissa Stiles; Konrad Kauper; Allyse Mazzarelli; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3294.

ARVO Annual Meeting Abstract June 2013

Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy

Konrad Kauper; Cahil McGovern; Paul Stabila; Sandy Sherman; Pam Heatherton; Brenda Dean; Crystal Cortellessa; Alice Lee; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3295.

ARVO Annual Meeting Abstract June 2013

Safety of implantation of the NT-503 device in patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration

Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado; Gustavo Sanchez-Bermudez; Fernando Schoonewolff; Samantha Salinas Longoria; Rafael Romero Vera; Weng Tao; Richard Beckman; Virgilio Morales-Canton; Asociacion para Evitar la Ceguera en Mexico I.A.P.

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3298.

ARVO Annual Meeting Abstract June 2013

Inhibition of choroidal neovascularization by neutralizing PDGF with a recombinant fusion protein of PDGFR β domain

Yiwen Li; Weng Tao; Vincent Ling; Arne Nystuen; Susan Elliott; Paul Stabila; Rong Wen

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4625.

ARVO Annual Meeting Abstract June 2013

Intraocular Delivery of Ciliary Neurotrophic Factor (CNTF) by Encapsulated Cell Technology Implants Restores Cone Function and Day Vision in Dogs with CNGB3 -Achromatopsia

Andras Komaromy; Kristin Koehl; Christine Harman; Pam Heatherton; Konrad Kauper; Gustavo Aguirre; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1718.

ARVO Annual Meeting Abstract June 2013

Long-term follow-up of patients with retinitis pigmentosa (RP) receiving sustained-release CNTF through intraocular encapsulated cell technology implants

David Birch; Kirsten Locke; Travis Porco; Martin Klein; Austin Roorda; Weng Tao; Jacque Duncan

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):640.

Clinical and Epidemiologic Research November 2012

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases

PDF

Konrad Kauper; Cahil McGovern; Sandy Sherman; Pam Heatherton; Rob Rapoza; Paul Stabila; Brenda Dean; Alice Lee; Suzanna Borges; Bruce Bouchard; Weng Tao
TAGS: ciliary neurotrophic factor, implants, degenerative disorders
Invest. Ophthalmol. Vis. Sci.. 2012; 53(12):7484-7491. https://doi.org/10.1167/iovs.12-9970

ARVO Annual Meeting Abstract March 2012

Development of an Optimized Culture Media to Improve VEGF Antagonist Secretion and Stability by Encapsulated Cell Technology Implants

Alline M. Lelis; Michael Rivera; Sue Elliott; Brenda Dean; Pam Heatherton; Bruce Bouchard; Melissa Stiles; Vicent Ling; Konrad Kauper; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):454.

ARVO Annual Meeting Abstract March 2012

Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases

Konrad Kauper; Vincent Ling; Sue Elliot; Cahil McGovern; Sandy Sherman; Brenda Dean; Lisa Orecchio; Mike Rivera; Pam Heatherton; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):455.

ARVO Annual Meeting Abstract March 2012

Evaluation of a Candidate Cell Line Employed to Deliver an Antiangiogenic Factor Using Encapsulated Cell Technology

Cahil McGovern; Sandy Sherman; Crystal Cortellessa; Suzanna Borges; Melissa Stiles; Karen Ahola; Alice Lee; Konrad Kauper; Bruce Bouchard; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):465.

ARVO Annual Meeting Abstract March 2012

Pharmacokinetics of a VEGF Antagonist Delivered by an Intraocular Encapsulated Cell Technology Implant

Michael Rivera; Alline Lelis; Bruce Bouchard; Melissa Stiles; Vincent Ling; Konrad Kauper; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):474.

ARVO Annual Meeting Abstract March 2012

Generation Of Dual Secreting CNTF / VEGF-antagonist Cell Lines And ECT Devices

Vincent Ling; Susan Elliott; Brenda Dean; Lisa Orecchio; Konrad Kauper; Michael Rivera; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):485.

ARVO Annual Meeting Abstract April 2011

Pharmacokinetics and Bioactivity of a Potent VEGF Inhibitor Following Sustained Intraocular Delivery to the Rabbit Eye Using Neurotech’s Encapsulated Cell Technology

Konrad Kauper; Paul Stabila; Vincent Ling; Sue Elliot; Cahil McGovern; Sandy Sherman; Mike Rivera; Alline Lelis; Pam Heatherton; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3223.

ARVO Annual Meeting Abstract April 2011

Evaluation of Candidate Cell Lines Employed to Deliver Different Antiangiogenic Factors Intraocularly Using Encapsulated Cell Technology

Cahil McGovern; Sandy Sherman; Crystal Cortellessa; Konrad Kauper; Michael Rivera; Melissa Stiles; Suzanna Borges; Vincent Ling; Bruce Bouchard; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3230.

ARVO Annual Meeting Abstract April 2011

A Phase 2 Study of Encapsulated CNTF-Secreting Cell Implant (NT-501) In Patients with Geographic Atrophy Associated with Dry AMD

Glenn J. Jaffe; Jaque L. Duncan; Weng Tao; CNTF Study Group

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1651.

ARVO Annual Meeting Abstract April 2011

Antibody Scaffold-based Biotherapeutics Are Secreted From Ophthalmic Ect Devices

Vincent Ling; Susan Elliott; Paul Stabila; Brenda Dean; Lisa D. Orecchio; Konrad Kauper; Cahil McGovern; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):474.

Clinical Trials April 2011

Longitudinal Study of Cone Photoreceptors during Retinal Degeneration and in Response to Ciliary Neurotrophic Factor Treatment

PDF

Katherine E. Talcott; Kavitha Ratnam; Sanna M. Sundquist; Anna S. Lucero; Brandon J. Lujan; Weng Tao; Travis C. Porco; Austin Roorda; Jacque L. Duncan
TAGS: ciliary neurotrophic factor, retinal cone, retinal degeneration, eye, longitudinal studies
Invest. Ophthalmol. Vis. Sci.. 2011; 52(5):2219-2226. https://doi.org/10.1167/iovs.10-6479

Retina November 2009

CREB1/ATF1 Activation in Photoreceptor Degeneration and Protection

PDF

William A. Beltran; Heather G. Allore; Elizabeth Johnson; Virginia Towle; Weng Tao; Gregory M. Acland; Gustavo D. Aguirre; Caroline J. Zeiss
TAGS: ciliary neurotrophic factor, dog, domestic, immunohistochemistry, photoreceptors, retina, tissue degeneration
Invest. Ophthalmol. Vis. Sci.. 2009; 50(11):5355-5363. https://doi.org/10.1167/iovs.09-3741

Includes: Supplemental Content

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

CNGB3 -Achromatopsia Clinical Trial With CNTF: Diminished Rod Pathway Responses With No Evidence of Improvement in Cone Function

Generation of Combination PDGF / VEGF-antagonist ECT devices

Feasibility of Cryopreservation of the Encapsulated Cell Technology Devices

Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy

Safety of implantation of the NT-503 device in patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration

Inhibition of choroidal neovascularization by neutralizing PDGF with a recombinant fusion protein of PDGFR β domain

Intraocular Delivery of Ciliary Neurotrophic Factor (CNTF) by Encapsulated Cell Technology Implants Restores Cone Function and Day Vision in Dogs with CNGB3 -Achromatopsia

Long-term follow-up of patients with retinitis pigmentosa (RP) receiving sustained-release CNTF through intraocular encapsulated cell technology implants

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases

Development of an Optimized Culture Media to Improve VEGF Antagonist Secretion and Stability by Encapsulated Cell Technology Implants

Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases

Evaluation of a Candidate Cell Line Employed to Deliver an Antiangiogenic Factor Using Encapsulated Cell Technology

Pharmacokinetics of a VEGF Antagonist Delivered by an Intraocular Encapsulated Cell Technology Implant

Generation Of Dual Secreting CNTF / VEGF-antagonist Cell Lines And ECT Devices

Pharmacokinetics and Bioactivity of a Potent VEGF Inhibitor Following Sustained Intraocular Delivery to the Rabbit Eye Using Neurotech’s Encapsulated Cell Technology

Evaluation of Candidate Cell Lines Employed to Deliver Different Antiangiogenic Factors Intraocularly Using Encapsulated Cell Technology

A Phase 2 Study of Encapsulated CNTF-Secreting Cell Implant (NT-501) In Patients with Geographic Atrophy Associated with Dry AMD

Antibody Scaffold-based Biotherapeutics Are Secreted From Ophthalmic Ect Devices

Longitudinal Study of Cone Photoreceptors during Retinal Degeneration and in Response to Ciliary Neurotrophic Factor Treatment

CREB1/ATF1 Activation in Photoreceptor Degeneration and Protection

To View More...

You must be signed into an individual account to use this feature.